151
Participants
Start Date
January 31, 2010
Primary Completion Date
April 30, 2011
Olodaterol (BI 1744)
Comparison of low and high doses on exercise endurance time in COPD patients
Olodaterol (BI 1744)
Comparison of low and high doses on exercise endurance time in COPD patients
Placebo
Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Olodaterol (BI 1744)
Comparison of low and high dose
Olodaterol (BI 1744) Placebo
Placebo that represents olodaterol
1222.37.6171 Boehringer Ingelheim Investigational Site, Daw Park
1222.37.6174 Boehringer Ingelheim Investigational Site, Clayton
1222.37.6173 Boehringer Ingelheim Investigational Site, Heidelberg
1222.37.6172 Boehringer Ingelheim Investigational Site, Melbourne
1222.37.4371 Boehringer Ingelheim Investigational Site, Gänserndorf
1222.37.4372 Boehringer Ingelheim Investigational Site, Neumarkt am Wallersee
1222.37.1072 Boehringer Ingelheim Investigational Site, Hamilton
1222.37.1074 Boehringer Ingelheim Investigational Site, Montreal
1222.37.1073 Boehringer Ingelheim Investigational Site, Ste-Foy
1222.37.33005 Boehringer Ingelheim Investigational Site, Béthune
1222.37.33002 Boehringer Ingelheim Investigational Site, Montpellier
1222.37.33001 Boehringer Ingelheim Investigational Site, Nîmes
1222.37.33006 Boehringer Ingelheim Investigational Site, Paris
1222.37.33004 Boehringer Ingelheim Investigational Site, Perpignan
1222.37.33003 Boehringer Ingelheim Investigational Site, Strasbourg
1222.37.4970 Boehringer Ingelheim Investigational Site, Berlin
1222.37.4972 Boehringer Ingelheim Investigational Site, Halle
1222.37.4973 Boehringer Ingelheim Investigational Site, Magdeburg
1222.37.4971 Boehringer Ingelheim Investigational Site, Rüdersdorf
Lead Sponsor
Boehringer Ingelheim
INDUSTRY